Here’s a polished English translation of the Chinese title: **Botox® (Allergan Aesthetics) Approved for Moderate to Severe Forehead Wrinkles in Adults**

Empowering Standardization and Quality Upgrade in the Medical Aesthetics Industry with Evidence-Based Medicine

ShanghaiApril 27, 2026 /PRNewswire/ — Allergan Aesthetics, a global leader in the medical aesthetics biopharmaceutical field, today announced that its product Botox^® has officially received marketing approval from the National Medical Products Administration (NMPA) for the temporary improvement of moderate to severe forehead lines associated with frontalis muscle activity in adults.

This marks the fourth medical aesthetics indication approved for Botox^® in China. The approval further enriches the clinical evidence for forehead line treatment, providing more reference points for the standardized and compliant development of facial rejuvenation treatments in the country.

Addressing Aesthetic Concerns, Rebuilding Confidence in Safety with Evidence-Based Data

Forehead lines, a common sign of upper facial aging, can sometimes make individuals appear more tired or serious than they actually are, becoming a concern for many seeking aesthetic improvements^[1]. However, due to the previous lack of specific registered indications, forehead line treatment in practice faced challenges such as off-label use, and a lack of unified reference standards for dosage and injection depth, leading to concerns about uncertain outcomes or unnatural expressions for some patients.

The approval of the Botox^® forehead line indication is based on the first Phase III registered clinical study specifically targeting moderate to severe forehead lines in Chinese adults. The data demonstrates favorable performance in both safety and efficacy^[2]. Additionally, a global study on Botox^® showed that in the treatment of upper facial wrinkles, including forehead lines, over 96% of patients were satisfied with the natural-looking treatment results on the upper face, and over 95% reported feeling more confident to express themselves after treatment^[3],[4],[5].

Professor Wu Wenyu, Director of the Dermatology Department at Huashan Hospital, Fudan University, and the principal investigator of the clinical study for this indication, stated: “The official approval of the Botox^® forehead line indication fills a critical gap in standardized forehead line treatment in China. It provides physicians with treatment references and evidence more tailored to the Chinese population in clinical practice, greatly enhancing the standardization and safety of clinical treatment. This will help drive the development of facial rejuvenation treatments in our country towards a more scientific and standardized direction.”

Leading the Industry with Compliance, Multi-Dimensional Initiatives Supporting Standardized Development in Medical Aesthetics

In recent years, compliance and standardization have become core directions for the development of the medical aesthetics industry. The approval of the Botox^® forehead line indication further completes the matrix of four medical aesthetics indications—glabellar lines, crow’s feet, masseter muscle prominence (hypertrophy), and forehead lines—solidifying its professional foundation for compliant treatment coverage in China and standardizing clinical treatment pathways from the source. This achievement deeply synergizes with Allergan Aesthetics’ ongoing “Three Standards” initiative and its full-chain product traceability system, ensuring product sources can be traced, destinations tracked, and responsibilities assigned. By guaranteeing authentic products and scientific standards, it promotes industry self-discipline and high-quality development, building a safe aesthetic barrier for consumers.

Professor Sun Jiaming, Director of the Wuhan Union Hospital Institute of Plastic Surgery, stated: “The expansion of Botox^®‘s medical aesthetics indications is highly significant for consumers. A rich portfolio of compliant indications can alleviate concerns about off-label drug use for both doctors and patients, allowing consumers to receive more comprehensive, safer, and more personalized standardized treatments without worrying about compliance and safety. This is a core benefit that the standardized development of the medical aesthetics industry brings to consumers.”

Deepening Clinical Practice, Triple Value Driving High-Quality Development of Forehead Line Treatment

The successful approval of the Botox^® forehead line indication is not only an important step for Allergan Aesthetics to deepen its presence in the Chinese medical aesthetics market and respond to clinical and consumer needs, but it also holds multiple values for the standardized development of the forehead line treatment field.

This approval, supported by high-quality clinical studies specific to the Chinese population, further promotes the development of this field towards standardization and evidence-based practice, providing the industry with a practical reference for compliant treatment supported by clinical data. For consumers, the implementation of a compliant indication helps improve forehead lines while better enabling overall upper facial expression management and natural expression, meeting aesthetic needs for facial rejuvenation under the premise of safety. Furthermore, a clear indication for forehead line treatment, combined with systematic and standardized training, helps physicians more precisely control injection dosage and depth, further enhancing clinical risk management capabilities.

Qiu Hanhua, Vice President of Allergan Aesthetics and General Manager of China, said: “The approval of the new Botox^® indication is a significant milestone for Allergan Aesthetics in deepening our presence in the Chinese market and meeting the diverse needs of consumers. We always prioritize consumer safety, closely follow the trend of industry compliance, and continue to deepen our commitment to evidence-based medicine and professional empowerment. We aim to build a standardized and healthy medical aesthetics ecosystem together with the industry, providing solid assurance for consumers to achieve beauty with peace of mind and renewed confidence.”